Literature DB >> 5785081

[Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].

R Tissot, J M Gaillard, M Guggisberg, G Gauthier, J de Ajuriaguerra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 5785081

Source DB:  PubMed          Journal:  Presse Med        ISSN： 0032-7867            Impact factor:   1.228


× No keyword cloud information.
  12 in total

1.  Possible mechanism of adverse reaction following levodopa plus benserazide treatment.

Authors:  F S Messiha
Journal:  Br J Pharmacol       Date:  1977-05       Impact factor: 8.739

Review 2.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

3.  Parkinson's tremor, relief by an antiaminic drug (BC 105). Discussion on the biochemical pathogenesis of Parkinsonian tremor.

Authors:  A Agnoli; M Casacchia; S Ruggieri; F Volante; N Accornero
Journal:  Z Neurol       Date:  1972

4.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

Review 5.  Dopamine and disease.

Authors:  A Barbeau
Journal:  Can Med Assoc J       Date:  1970-10-17       Impact factor: 8.262

6.  Parkinson's disease and striatal dopamine: in vivo morphological evidence for the presence of dopamine in the human brain.

Authors:  J Constantinidis; J Siegfried; T L Frigyesi; R Tissot
Journal:  J Neural Transm       Date:  1974       Impact factor: 3.575

7.  [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease].

Authors:  E Schneider; P A Fischer; P Jacobi; H Maxion
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1973-03-19

8.  [The therapeutic effect of L-dopa].

Authors:  P Groneberg; A Struppler
Journal:  Naturwissenschaften       Date:  1972-11

9.  Treatment of Parkinson's disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxylase.

Authors:  C D Marsden; P E Barry; J D Parkes; K J Zilkha
Journal:  J Neurol Neurosurg Psychiatry       Date:  1973-02       Impact factor: 10.154

Review 10.  L-dopa therapy in Parkinson's disease: a critical review of nine years' experience.

Authors:  A Barbeau
Journal:  Can Med Assoc J       Date:  1969-12-27       Impact factor: 8.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.